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Abstract: NUT midline carcinoma (NMC) is a rare and aggressive subtype of squamous
carcinoma that typically arises from midline supradiaphragmatic structures, frequently
from the head and neck area. NMC is genetically driven by a chromosomal rearrange-
ment involving the NUT gene, which forms oncoproteins considered major pathogenic
drivers of cellular transformation. Diagnosis of NMC has been made remarkably easier
with the availability of a commercial antibody against NUT, and can be established
through positive nuclear immunohistochemical staining. Although NMC remains an
underrecognized malignancy, in recent years there has appeared to be increasing aware-
ness of disease and frequency of diagnosis in adults. To date, a standard treatment for
head and neck NMC has not been established and a multimodal approach with systemic
chemotherapy, surgery and radiation therapy is currently adopted in clinical practice.
Recently, BET inhibitors and histone deacetylase inhibitors have emerged as two promis-
ing classes of targeted agents, currently investigated in clinical trials for adults with head
and neck NMC. At the same time, combination approaches and novel targeted agents,
such as next-generation BET inhibitors and CDK9 inhibitors, have shown preclinical
activity. The present review explores the clinical pathological characteristics of NMC of
the head and neck and presents the current state of the art on diagnosis, prognosis, and
treatment of this rare but lethal disease.
Keywords: NUT midline carcinoma, head and neck, BRD4-NUT, BET inhibitors, histone
deacetylase inhibitors
Introduction
NUT midline carcinoma (NMC) is a genetically defined epithelial malignant
neoplasm hallmarked by chromosomal rearrangement of the NUT gene. The most
common rearrangement is a translocation between the NUT and BRD4 gene,
forming the BRD4–NUT oncoprotein that is considered a major pathogenic driver
of cellular transformation.1 In a third of cases, variant NUT rearrangements involve
other genes, such as BRD3 and NSD3.2 Consistent with their oncogenic function of
blocking epithelial squamous differentiation, fusion proteins maintain the prolifera-
tion of immature neoplastic cells, providing a rationale for targeting these proteins.
Initially described in children and adolescents, it is now clear that NMC can
develop in males and females of all ages, although its true incidence remains
unclear.3 NMC typically arises from midline supradiaphragmatic structures: the
upper aerodigestive tract (50%) and the mediastinum (41%).4 However, rarer
cases have been diagnosed below the diaphragm (bladder)5 and outside the midline
axis (major salivary glands, iliac bone, adrenal gland, and pancreas).6–8
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NMC is considered the most aggressive subtype of
squamous carcinoma, with >80% of patients dying within
1 year of diagnosis. Treatment approaches have been het-
erogeneous over the years, and no standard has yet been
established. Novel targeted agents, such as histone deace-
tylase inhibitors (HDACis) and BET inhibitors (BETis),
hold great promise alone or in combination with che-
motherapy. Because of the disease's rarity, an international
NMC registry has been in development since 2010 to
pursue a twofold aim. The first is to raise awareness and
disseminate information about NMC. The second is to
collect clinical data on the disease and its response to
treatment, creating a repository of clinical specimens that
will support future research.
The present paper reviews the clinical pathological
characteristics of head and neck NMC (HNNMC) and
presents the current state of the art on diagnosis, prog-
nosis, and treatment of this rare but lethal disease.
Clinical presentation and outcome:
a rare and devastating disease
Approximately 39% of NMCs arise from the head and
neck region, while the sinonasal area is the most common
tumor site, followed by the nasopharynx, oropharynx,
hypopharynx, larynx, and unknown primary site.9 The
true incidence of HNNMC remains unknown, but
increased awareness of the disease and the availability of
new easily applicable diagnostic tests could explain both
the apparent increase in the frequency of diagnosis, parti-
cularly since 2012, and the greater number of adult
cases.3,10 In the largest HNNMC cohort reported in the
literature to date, the median age at diagnosis was 21.9
years, with the majority of tumors occurring in females.10
The presumed rarity of HNNMC, coupled with its occur-
rence in young age with minimal smoking history and lack
of pathognomonic histopathological features, suggests that
the disease remains underrecognized. Only a minority of
cases are diagnosed with NMC at the beginning, while the
most common incorrect original diagnoses are “poorly
differentiated carcinoma” or “poorly differentiated squa-
mous carcinoma”.10 Due to the small number of patients,
no epidemiological studies of etiologic factors have been
conducted. Nevertheless, there is no evidence that smok-
ing or other environmental factors are associated with
HNNMC. In particular, no cases diagnosed to date have
been associated with Epstein–Barr virus or human papil-
loma virus (HPV) infection.
HNNMC runs a devastating clinical course. It usually
presents with rapidly enlarging masses, characterized at
advanced stages by early metastatic spread to either locor-
egional lymph nodes or less common distant sites.3
Consequently, most patients present with mass-related
symptoms (such as rhinorrhea, epistaxis, nasal obstruction,
proptosis, diminished vision, dysphagia, or pain), while
aspecific symptoms, such as fever and weight loss, have
been seen only occasionally.11
Genetic background: a molecularly
defined cancer
The genetic hallmark of NMC is the chromosomal rearrange-
ment of theNUT gene (also known asNUTM1 orChr15orf55),
first described in 2003 by French et al (Figure 1).12 In two-
thirds of NMCs, a reciprocal chromosomal translocation
involves the NUT gene on chromosome 15q14 and BRD4 on
chromosome 19p13.1 (Figure 1). The BRD4 protein, encoded
by the BRD4 gene, is the most extensively studied member of
the BET protein family, first identified by Jiang et al in
1988.13,14 The classical translocation t(15;19)(q14;p13.1)
fuses exon 3 of the NUT gene to exon 11 of the BRD4 gene.
This results in an in-frame fusion gene of 6.4 kb that encodes
a BRD4–NUT oncoprotein involved in carcinogenesis and
driven by the BRD4 promoter.112,3–5,5,6–1818 Although three
isoforms of the BRD4 protein have been described (called A,
B, and C), only isoform C, ubiquitously expressed, is involved
in the BRD4–NUT fusion protein.19 The BRD4–NUT fusion
gene contains the whole coding region for NUT, which is
entirely included in the fusion process, while BRD4 loses
its C-terminal domain, including all of its functional
domains (Figure 2).
On the other hand, in a third of NMCs, the NUT partner
genes are BRD3 (Figure 1), NSD3 (Figure 1) or other
uncharacterized genes.1,15 In these rearrangements, the
entire NUT structure is maintained in the fusion oncogene,
along with the bromodomains, the extraterminal domain
and the bipartite nuclear localization sequence of BRD3
(Figure 2). Instead, NSD3 is an enzymatic protein involved
in the methylation of histone lysine marks, regulating chro-
matin integrity and gene expression. Only the N-terminus of
NSD3 is included in the genetic fusion process, whereas its
methyltransferase domain is absent (Figure 2).20
Rare cases of NMC inwhichNUT is fused to a zinc finger–
containing protein, such as ZNF532 and ZNF592, have
recently been described in the literature.21,22 ZNF532 is
involved in feed-forward regulatory loops that drive
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propagation of the oncogenic chromatin complex in
BRD4–NUT cells. ZNF532, as well as BRD3 and NSD3,
interacts with BRD4, and its fusion with NUT results in
a powerful oncogenic complex. All these rare fusion partners
of NUT are functionally related to BRD4, indicating that the
recruitment of NUT to chromatin through the BET family
proteins is necessary in NMC pathogenesis. For these reasons,
NMC is considered the prototype BET-driven cancer, offering
15q14
NUT AD1
19p13.12
BRD4 BD1 BD2 NLSET CTD
9q34.2
BRD3 BD1 BD2 NLS ET
8p11.23
NSD3 PWWP PWWPPHD SET PHD
AD2 NESNLS
Chromosome 15
Chromosome 19
Chromosome 9
Chromosome 8
Figure 1 Schematic representation of native component genes and domain structures of BET proteins (BRD3, BRD4), NSD3, and NUT.
Note: Black bars on chromosomes indicate location of translocation-associated break points.
Abbreviations: AD, acidic domain; NES, nuclear export signal; NLS, nuclear localization sequence; ET, extraterminal; CTD, C-terminal domain; PWWP, proline–
tryptophan–tryptophan–proline; PHD, plant homeodomain.
BRD3
BRD4
NSD3
BD1 BD2
BD1
PWWP
BD2
NLS
NLS
AD1
AD1
AD1
AD2
AD2
AD2
NLS
NES
NLS
NES
NLS
NES
ET
ET
NUT
NUT
NUT
Figure 2 Schematic representation of fusion oncoproteins involved in NMC.
Note: In every fusion oncoprotein, the entire NUT structure is included.
Abbreviations: AD, acidic domain; NES, nuclear export signal; NLS, nuclear localization sequence; ET, extraterminal; PWWP, proline–tryptophan–tryptophan–proline.
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an opportunity to study both oncogenic BRD4 pathways and
the effects of its potential inhibition.
Interestingly, several studies have shown that mutation
type did not affect prognosis in NMC patients, although
a recent work reported a better outcome for NSD3- or
BRD3–NUT-positive HNNMC than for those with
BRD4–NUT.3,18 However, since most patients carry the
BRD4–NUT translocation, leading to a lack of statistical
power, the prognostic impact of the translocation type
remains unclear.
Several in vitro studies with patient-derived tumor cells
using knockdown of BRD3/4–NUT and NSD3–NUT genes
have provided evidence of terminal and irreversible squa-
mous differentiation and growth arrest.1,2 This observation
indicates that NUT fusion proteins act to maintain growth
and block squamous-cell differentiation, by suppressing
transcription and decreasing histone acetylation23 in
a mechanism dependent on the targeting of MYC and
TP63 genes by BRD.18,21
From diagnosis to prognostication
Imaging
Although the radiological features of NMC are not speci-
fic, their appearance may be indicative of aggressive
malignancy, with a propensity to invade neighboring
structures.24 Computed tomography is generally character-
ized by heterogeneous enhancement of an infiltrative or
destructive-appearing primary mass and low attenuation of
pathological lymph nodes, related to evidence of necrosis
and hemorrhage in the surgery samples. Magnetic reso-
nance imaging represents the gold standard for diagnosis
and correct staging of HNNMC, providing superior soft-
tissue delineation compared to computed tomography for
evaluation of masses involving the head and neck, as well
as the musculoskeletal system. Additionally, magnetic
resonance imaging plays an important role intreatment
planning, providing critical information, such as the pre-
sence of vascular invasion, perineural involvement, and
skull-base invasion. Fludeoxyglucosepositron-emission
tomography should be used after confirmed diagnoses of
HNNMC to assess the presence of distant metastases,
although it may underestimate disease burden, because of
low-level fludeoxyglucoseuptake in necrotic areas.25
Cytogenetics and histopathology
A distinctive feature of HNNMC is a remarkably simple
karyotype, often with a single translocation as its sole
cytogenetic aberration, classically a reciprocal t(15;19)
(q14;p13.1).5 This finding distinguishes HNNMC from more
common head and neck carcinomas, including squamous-cell
carcinomas of adulthood, which exhibit complex aneuploid
karyotypes and high mutational burden.26
The histopathological features of HNNMC are charac-
teristic, though not diagnostic. The most common appear-
ance is that of a poorly differentiated carcinoma with focal
or extensive abrupt keratinization.27 Tumors are usually
composed of sheets of undifferentiated medium-size and
oval cells with scant amphiphilic or eosinophilic cyto-
plasm (called “fried egg”-like cells). Characteristically,
the cells are monomorphic in appearance, in contrast to
other poorly differentiated carcinomas, which consist of
striking pleomorphic cells. They have typically vesicular
chromatin and prominent nucleoli. Foci of necrosis can be
present and mitotic figures are common, reflecting rapid
tumor growth. Although infiltrating lymphocytes can occa-
sionally be found, the presence of neutrophilic infiltrates is
more common and can be prominent. The unusual patho-
logical pattern occurring in the salivary glands exhibits
prominent mesenchymal differentiation, including the pre-
sence of myxoid matrix or cartilage.7
When to perform the NUT IHC test
The diagnosis of HNNMC has been made remarkably easier
with the availability of a commercial antibody against NUT
(clone C52B1) from Cell Signaling Technologies (Danvers,
MA, USA). This monoclonal rabbit antibody, developed on
the basis of knowledge that NUT expression should not
normally be seen outside the testes, can be used routinely in
the community to detect NUT expression by immunohisto-
chemistry (IHC).15 While germ-cell tumors and rare poorly
differentiated carcinomas can be stained only focally
(<10%), NMC diagnosis by IHC with the NUT antibody
reveals diffuse nuclear staining, often with a speckled pat-
tern. Haack et al verified the accuracy of the C52B1 antibody
to detect NUT rearrangement confirmed by fluorescent in situ
hybridization. They demonstrated 87% sensitivity and 100%
specificity; therefore, strongly positive staining is virtually
diagnostic of NMC.28 In particular, following the World
Health Organization, IHC staining >50% of tumor nuclei is
considered diagnostic of NMC.29,30 Although not required to
confirm diagnosis, various molecular analyses able to
demonstrate NUT rearrangement can be used if the mono-
clonal antibody is not available. These methods include
fluorescence in situ hybridization (FISH), reverse-transcript
ion PCR, cytogenetics and next-generation sequencing-based
Napolitano et al Dovepress
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approach. Fluorescence in situ hybridization is the preferred
assay, because it detects all NMCs,5 including atypical fusion
break points between BRD4/BRD3 and NUTM1, as well as
rare fusion partners to NUTM1, whereas reverse-transcript
ion PCR can currently only detect BRD3– or BRD4–NUT
tumors and is probably the least sensitive approach.31,32
Fusion-partner characterization may have a clinical impact
in view of recent data that indicate a better prognosis for
NSD3- or BRD3–NUT-positive HNNMC patients than for
those with BRD4-NUT.9
Today, the challenge is no longer diagnosing NMC, but
determining when to perform the test. With greater aware-
ness of HNNMC and with the availability of this simple
diagnostic assessment, the number of diagnosed HNNMC
cases is increasing, and it is likely it will continue to
increase. NUT IHC testing is recommended in all poorly
differentiated noncutaneous carcinomas of the head and
neck with or without squamous differentiation that exhibit
a monomorphic pattern. Tumors with glandular differen-
tiation (extremely rare in HNNMC) should not be tested,
and viral etiology (such as HPVor Epstein–Barr virus) can
be used to exclude HNNMC diagnosis. Interestingly, in
many HNNMC cases, strong p16 expression for can be
present. However, this are not positive for HPV evaluated
by PCR, indicating that HPV infection does not play a role
in the pathogenesis of HNNMC.33
Risk categories and prognosis
Due to NMC's rarity and under-diagnosis, there are no
existing models to classify patients into risk groups
based on baseline clinicopathological factors. Recently,
Chau et al developed a prognostic risk classification
model for NMC survival outcomes based on the largest
cohort of NMC patients analyzed to date, identifying three
distinct risk groups: patients without lymph-node or organ
metastases, patients with lymph-node or organ metastases
and nonthoracic origin, and patients with metastases and
thoracic origin.9 The authors concluded that the group of
metastatic patients and thoracic primary tumors
had markedly poorer prognosis than other subgroups.
Another factor that shows an impact on outcome is
tumor size, with worse prognosis for larger tumors
(>5 cm) than smaller tumors.18
Although data regarding HNNMC are mainly restricted
to case reports with limited treatment and follow-up informa-
tion, a retrospective review of all HNNMC cases in the
International NUT Midline Carcinoma Registry was per-
formed. HNNMC showed slightly better survival outcomes
than thoracic NMC, based on historical comparison, with
median survival of months and 2-year overall survival of
30%.3,10 Despite the small number of cases reported to date
and the lack of prospective comparisons, Chau et al showed
that complete surgical resection with no residuum was asso-
ciated with significantly improved survival, in particular for
tumors <6 cm in size. The initial therapeutic sequencing
strategy seemed to be the most critical factor to affect prog-
nosis. Chemotherapy and radiation alone were often inade-
quate, even though both may be important as adjuvant
treatment. Other clinical or pathologic features, including
sex, age, and type of chemotherapy regimen, were not asso-
ciated with survival outcomes, while the role of
NUT-translocation type was unclear because the majority of
patients had BRD4–NUT translocation.
Therapeutic management: from
orphan to target disease
Despite the fact that a standard treatment for HNMMC has
not been established yet, a multimodal approach with
systemic chemotherapy, surgery, and radiation therapy is
adopted in clinical practice. Due to the rarity of the disease
and the ununiform treatments administered, it has been
challenging to evaluate the efficacy of various therapeutic
approaches.3 When feasible, surgery is usually considered
the primary option associated with improved outcome. In
a report from the NUT Midline Carcinoma Registry, 40
patients with HNMMC were evaluable, and 2-year overall
survival was 30%, with the three long-term survivors (35,
72, and 78 months) undergoing primary gross–total resec-
tion and adjuvant therapy.10
Despite the small number of cases and the lack of
prospective comparison, this report showed that com-
plete surgical resection was associated with significantly
improved survival in contrast with initial radiation or
chemotherapy, which did not seem to have an impact
on survival. Since survival appears to be affected by
response to initial therapy, the treatment sequencing
strategy becomes critical to the management of
HNNMC. However, the disease is often locally advanced
and/or distantly metastatic at diagnosis. Because of that,
complete resection often cannot be safely performed and
most patients receive postoperative radiation or
chemotherapy.18 A variety of radiation therapy and che-
motherapy modalities have been used in both the adju-
vant setting and the exclusive setting. These
heterogeneous systemic therapies included intensive
Dovepress Napolitano et al
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chemotherapy regimens commonly applied in the event
of other carcinomas, sarcomas, germ cell tumors and
other solid neoplasms. In particular, Cisplatin, taxanes
and alkylating agents have been used with some
success.11,16,34 However, while rapid response is com-
mon, tumor progression occurs early in a treatment-
refractory manner and the overall outcome for these
patients remains poor.35
Preclinical studies have shown that the NUT-BRD4
fusion is associated with globally decreased histone acet-
ylation and transcriptional repression.Studies have also
shown that this acetylation can be restored with histone
deacetylase inhibitors, resulting in squamous differentia-
tion and arrested growth in vitro and growth inhibition in
xenograft models.23,36 BET inhibitors (BETi) and HDACi
represent two promising class of agents that are being
investigated for adults with HNNMC, either alone or in
combination with chemotherapy.
BET inhibitors (BETi): another way to
target BRD-NUT
On the basis of the main role of bromodomain-containing
NUT fusion proteins in NMC development, inhibitors of
bromodomain of BET proteins have been investigated
with promising leads. BET inhibitors are acetyl-lysine
mimetic compounds that bind the acetyl-lysing binding
pocket of both bromodomains (BD1 and BD2) of all
BET proteins including BRDT, BRD2, BRD3 and
BRD4.37 Therefore, the antitumor activity of these small
molecules derives from the interruption of interactions
between BET proteins and acetylated lysine in histones
at promoters and enhancers. Originally identified in small
molecules used to treat autoimmune disease, they were
later discovered for their BET inhibitory properties.37
JQ1, a first-in-class BETi, causes dissolution of BRD4-
NUT nuclear speckles resulting in rapid terminal differen-
tiation, apoptosis and growth arrest of cultured NMC cells,
as demonstrated by immunocytochemistry with an antiker-
atin (AE1/AE3) antibody.20 In vivo, JQ1 (administered at
50 mg/kg daily) induced the suppression of tumor growth
and improved survival in NMC xenograft models, pro-
vided the proof of principle that the inhibition of BRD4
by BETi can be therapeutically targeted.38 Since then,
there has been an explosion of clinical trials using BETi
in solid and liquid tumors.39–44
Birabresib (MK-8628/OTX015) is a novel BET inhibi-
tor currently in clinical development. It targets BRD2/3/4
with preclinical activity in NMC and several other cancers,
particularly selected hematologic tumors.43,45,46 A recent
phase Ib study evaluating Birabresib in patients with
selected advanced solid tumors, including NMC, high-
lighted a clinical activity of particular interest for
NMC.47 Of the nine evaluable patients with NMC, six
demonstrated partial response (PR) or stable disease
(SD), with three patients having a PR and a favorable
tolerability profile of reversible and self-limiting thrombo-
cytopenia that required dose modification. Previously,
Stathis et al described the outcomes of four NMC patients
treated with Birabresib outside a clinical trial, reporting
dramatic and rapid response with symptomatic improve-
ment in two patients and stable disease in another.38
Interestingly, though all patients eventually died of the
disease, two of them had reached an overall survival of
18 and 19 months, markedly longer than the mOS reported
in the largest retrospective HNNMC and NMC cohorts
published to date (9.7 and 6.7 months respectively).3,10
Since these drugs inhibit all BET proteins expressed in
most tissues, it is not surprising that toxicity limited their
efficacy in NMC. The most common types of toxicity are
diarrhea, nausea, decreased appetite and thrombocytope-
nia. These derive from a repression of transcription in
erythroid and megakaryocytic genes and represent the
most common treatment-related serious event requiring
dose modification and also treatment interruption.47,48 As
for other target therapies, the initial but only transient
response to treatment with BETi suggests the emergence
of secondary resistance mechanisms that might differ
according to cancer type. These mechanisms could include
restoration of MYC expression through the WNT pathway
or BRD4 phosphorylation.40,49–51 Recently, Liao et al sys-
tematically explored about 900 tumor suppressor genes
and oncogenes for their ability to mediate resistance of
NMC to BETi. By using high-throughput loss-of-function
and gain-of-function screening technologies, they identi-
fied six pathways mediating resistance.52 Among these, the
authors highlighted multiple ways for NMC cells to bypass
the cell cycle arrest induced by BETi, including up-
regulation of cyclin D1 or cyclin D3 mutant or RB1 loss.
In accordance with this finding, CDK4/6 inhibitors showed
synergistic activity with JQ1 on NMC in vitro and in vivo,
providing a rationale for combination therapy of BETi and
CDK4/6 inhibitors for this malignancy.
Several other trials on BETi enrolling NMC patients
are ongoing (Table 1) and multiple additional studies are
enrolling patients with hematologic and solid cancers.
Napolitano et al Dovepress
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Histone deacetylase inhibitors (HDACi)
BRD4/NUT protein is suggested active histone acetyl-
transferase p300, thereby sequestering histone acetyltrans-
ferase activity to localized regions of BRD4-NUT-acetyl-
chromatin binding. This results in an overabundance of
HDAC activity outside of these regions, which leads to
global hypoacetylation and transcriptional repression of
genes required for differentiation.53 It has been hypothe-
sized that these effects can be reversed by hyperacetylating
histones artificially with the use of HDACi, restoring
chromatin acetylation and increasing the transcription of
pro-differentiative genes.
In xenograft models of NMC, HDACi significantly
inhibited growth, induced differentiation and improved
survival, providing preclinical support for the use of
HDACi as targeted therapeutic agents for NMC. Based
on these findings, Vorinostat, a histone deacetylase inhibi-
tor, has been used clinically with dramatic objective
response, before adverse effects limited its use.23,36 In
contrast, Maur et al described a clinical case of ineffective
treatment with Romidepsin, another HDACi currently stu-
died in a variety of cancers, possibly due to primary
resistance or secondary resistance mechanisms such as
parallel pathway activation, drug-induced de novo genetic
variations or target gene change.35
Currently, a phase I trial (NCT02307240) evaluating
the safety, tolerability and pharmacokinetics of CUDC-
907, a dual HDACi/PI3K inhibitor, is open to enrolling
NMC patients (Table 1). The antitumor activity of
CUDC-907 against NMC cells has been demonstrated
in vitro and in animal models and appears to be asso-
ciated with MYC protein downregulation, a major target
of BET proteins, induced by HDAC and PI3K inhibition
synergistically.54 HDAC inhibition potently suppresses
MYC expression at the transcriptional level, while PI3K
inhibition results in enhanced ubiquitin-mediated MYC
protein degradation at the post-translational level.
Munster et al reported a case of prolonged disease stabi-
lization for over 32 months in an NMC patient treated
with CUDC-907 after two prior treatments.55
Future perspectives: novel targeted
agents and combination approaches
Despite the initial response, all NMC patients treated with
BETi or HDACi develop resistance and relapse during treat-
ment. Therefore, an urgent need to develop effective combi-
nation therapies and alternative therapeutic approaches
arises. Recently, CDK9 has emerged as new non-oncogenic
driver that is potentially and directly druggable. Together
with Cyclin-T1, CDK9 forms the positive transcription elon-
gation factor b (P-TEFb) complex, whose recruitment by
BRD4 is required for BRD4-dependent transcriptional
elongation.56 A study in vitro demonstrated that CDK9 inhi-
bitors lead to robust induction of apoptosis and induction of
DNA damage response in NMC cells, suggesting that CDK9
may be an attractive drug target in NMC patients.57 Beesley
et al compared the efficacy of the CDK9 inhibitor flavopir-
idol (FP) with a panel of antitumor agents in NMC cell lines
and animal models, finding that FP was one of the most
cytotoxic drugs in vitro associated with significant in vivo
responses.58 An oral phosphate prodrug of the CDK9 inhi-
bitor (Alvocidib) is being tested in a phase 1 trial enrolling
patients with advanced solid tumors, including those
with NMC.
Much preclinical evidence of synergism between BETi
and different classes of compounds has been reported in
different tumor types that have been investigated. In parti-
cular, preclinical studies highlighted that BETi shows
synergism with immune checkpoint modulators.59,60 JQ1
was seen to regulate expression of the immune checkpoint
Table 1 Ongoing or already available clinical trials of targeted therapy for NMC
NCT identifier Drug Target Phase Status
NCT01587703 GSK525762 BRD2/3/4 I/II Active, not recruiting
NCT02698176 OTX015/MK8628 BRD2/3/4 I Terminated (due to limited efficacy and not due to safety reasons)
NCT03702036 GSK525762 BRD2/3/4 Expanded access Available
NCT01987362 RO6870810 BRD2/3/4 I Completed
NCT02259114 OTX015/MK8628 BRD2/3/4 Ib Completed
NCT02711137 INCB057643 BRD2/3/4 I/II Active, not recruiting
NCT02431260 INCB054329 BRD2/3/4 I/II Completed
NCT02307240 CUDC-907 HDAC/PI3K I Recruiting
NCT02369029 BAY1238097 BRD2/3/4 I Terminated
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ligand PD-L1 and to correlate with increased anti–tumor
cytotoxic T cells.61 The combination of JQ1 with PD-1
blockade in a KRAS mutant NSCLC xenograft leads to
synergistic tumor burden reduction.62 Furthermore, the
combined inhibition of histone deacetylases and the pro-
teins of the BET family have recently shown therapeutic
efficacy in a number of in vitro and in vivo cancer models
including melanoma, pancreatic ductal adenocarcinoma,
testicular cancer and lymphoma.63–66 Taken together,
these findings highlight the potential of combination ther-
apy for BETi with newer agents.
Recently, Stirweiss and colleagues performed next-
generation sequencing on a large panel of NMC cell lines
to understand the molecular-genetic landscape of NMC,
a critical step towards developing novel therapeutic
approaches.67 They identified a recurring high-impact muta-
tion in the RECQL5 gene, which encodes for a DNA-
helicase involved in interstrand crosslinking repair, and
a network analysis consistent with general failure in DNA-
repair.68 These findings provide preliminary evidence of
a potential defect in the processes of DNA-repair within the
genome of NMC cells. On thesegrounds, it is conceivable
that the mutation of RECQL5 promotes the acquisition of
additional mutations necessary for the NMC phenotype,
leading to genetic instability that could be explored to
improve therapeutic strategies. Furthermore, in keeping
with a recent publication demonstrating that BETi directly
suppresses the aurora kinases genes (AURKA and AURKB)
in triple negative breast cancer cells, the authors identified
a significant correlation between BETi and AURK inhibitors
efficacy.69
It is likely that recent and future investigation on genes
that drive cancer development and progression could elu-
cidate the genetic landscape of resistance to BETi and
identify combinations that might overcome adaptive resis-
tance mechanisms to NMC therapy. More efforts in
research at molecular and clinical levels remain crucial
for a rare and lethal cancer such as NMC.
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